Tango Therapeutics, Inc. (TNGX)
9.63
-0.27
(-2.73%)
USD |
NASDAQ |
Dec 05, 16:00
9.69
+0.06
(+0.62%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.296B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 177.5% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 15.95 |
| Price to Book Value | 8.099 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2172 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 93.64% |
Profile
| Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA. |
| URL | http://www.tangotx.com |
| Investor Relations URL | https://ir.tangotx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 26, 2026 (est.) |
| Last Earnings Release | Nov. 04, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA. |
| URL | http://www.tangotx.com |
| Investor Relations URL | https://ir.tangotx.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 26, 2026 (est.) |
| Last Earnings Release | Nov. 04, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |